Trial of Pimasertib in Hematological Malignancies

NCT00957580 PHASE2 TERMINATED Results posted

This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study drug in subjects with advanced hematological malignancies. Part 2: Will assess the anti-leukemic activity of the study drug in older subjects with newly diagnosed poor prognosis acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.

Details

Lead sponsor	EMD Serono
Phase	PHASE2
Status	TERMINATED
Enrolment	81
Start date	Wed Sep 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Leukemia, Myeloid, Acute
• Hematologic Neoplasms

Interventions

• Pimasertib
• Pimasertib
• Pimasertib
• Pimasertib
• Pimasertib

Countries

France, United States